People switching to Novo's Wegovy pill from obesity injections kept losing weight in real-world study
Real-world study data reveals patients switching from obesity injections to Novo Nordisk's oral Wegovy pill continue to lose weight.
Velocity
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
The brief
Recent coverage from outlets including Reuters, CNBC, BioSpace, FirstWord, The Pharma Letter, PR Newswire, marketscreener.com, and qz.com details new findings regarding Novo Nordisk's oral Wegovy pill. According to the reported data, patients who transition from injectable GLP-1 obesity treatments to the oral version of Wegovy continue their weight loss trajectory in real-world settings. The findings were presented at the EASD meeting, highlighting clinical and observational observations about patient outcomes following a medication switch. In addition to the scientific data presentations, coverage from BioSpace and PR Newswire highlights a newly announced research collaboration between Ro and Novo Nordisk.
This partnership aims to generate first-of-its-kind real-world evidence specifically examining the Wegovy pill. Outlets emphasize that this data provides concrete confirmation of the oral medication's effectiveness outside of strictly controlled clinical trial environments, offering valuable insights into everyday patient usage and therapeutic continuity. This trend emerges as pharmaceutical companies and telehealth providers increasingly focus on oral alternatives to traditional injectable weight-loss therapies. The shift toward pill-based options addresses patient preferences and practical administration concerns in the broader obesity treatment landscape.
Coverage notes that the data specifically tracks individuals who previously relied on injectable medications, establishing a direct comparison point for treatment efficacy during a medication transition. Future developments will depend on further data releases from the announced research collaboration between Ro and Novo Nordisk, as well as additional presentations at medical congresses such as EASD. Observers and market participants will monitor how real-world evidence regarding the oral Wegovy pill influences prescribing habits, patient retention, and commercial adoption relative to incumbent injectable obesity treatments.
Synthesized by PULSE from the headlines below under a strict no-invention contract. ✓ fact-checked: all claims supported by sources Updated 48d ago.
Quick answers
What did the real-world study find about the Wegovy pill?
Coverage states that people switching from injectable obesity treatments to Novo's oral Wegovy pill continued losing weight.
Which companies are involved in the newly announced research collaboration?
According to PR Newswire and BioSpace, Ro and Novo have announced a research collaboration to generate real-world evidence on the Wegovy pill.
Where were the findings presented?
FirstWord reports that the findings were presented at the EASD.
Coverage (10)
- Oral Wegovy option confirms its effectiveness in real-world data marketscreener.com · 49d ago
- Ro and Novo Announce Research Collaboration to Generate First-of-its-Kind Real-World Evidence on the Wegovy® Pill BioSpace · 49d ago
- Peptide Ruling Stalls Pharmaceutical Executive · 49d ago
- Novo Nordisk Wegovy pill weight loss switch study results Yahoo Finance · 49d ago
- EASD: Novo says people switching from injectable GLP-1s to oral Wegovy continue losing weight FirstWord · 49d ago
- Real-world study shows continued weight loss after switching to oral Wegovy The Pharma Letter · 49d ago
- Ro and Novo Announce Research Collaboration to Generate First-of-its-Kind Real-World Evidence on the Wegovy® Pill PR Newswire · 49d ago
- Patients switching to Novo Nordisk's Wegovy pill from shots lose more weight in real-world study Reuters · 49d ago
- Novo Nordisk Wegovy pill weight loss switch study results qz.com · 49d ago
- People switching to Novo's Wegovy pill from obesity injections kept losing weight in real-world study CNBC · 49d ago
Topics
Related trends
GLP-1 poison calls surge in Georgia as experts warn about unapproved weight-loss drugs - WSB-TV
Georgia poison centers report a surge in calls linked to GLP-1 weight-loss drugs as experts flag risks from unapproved versions.
Should you take GLP-1s during pregnancy? What some doctors say.
New research on GLP-1 drugs during pregnancy sparks urgent debate among doctors and patients.
Novo says Wegovy injection lowers BMI and obesity rates in children in trial
Novo Nordisk reports Wegovy injection reduced BMI and obesity rates in children as young as six in a clinical trial, expanding the drug's potential pediatric use.
WHO Releases First Guidelines On Type 1 Diabetes In Adults: What To Know
WHO publishes its first-ever clinical guidelines for type 1 diabetes in adults, urging cheaper insulin access and multiple daily injections.
The GLP-1 boom has a dark side
FDA orders new eye-risk warnings on a dozen GLP-1 drugs, including Ozempic and Zepbound, amid reports of vision-threatening events.
Taking GLP-1s forever? 5 strategies to keep weight off if you stop
New Cleveland Clinic research maps five evidence-based exit strategies for patients discontinuing GLP-1 weight-loss drugs, a question facing millions as supply and cost pressures mount.